Major Shareholder Announcement re shareholder proxies given to the board of directors for the EGM 23 July 2009.

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com


Referring to executive order no. 1225/2007 (the executive order on major
shareholders), Section 4, no. 8, TopoTarget A/S hereby announces that the board
of directors of TopoTarget A/S has received shareholder proxies to vote at
TopoTarget A/S' Extraordinary General Meeting to be held Thursday 23 July 2009,
meaning that TopoTarget A/S (represented by its board of directors) holds 23.1%
of the voting rights in TopoTarget A/S. 

After the Extraordinary General Meeting the proxies will expire and TopoTarget
A/S (represented by its board of directors) will thereafter hold 0% of the
voting rights in TopoTarget A/S. 


TopoTarget A/S
	

For further information, please contact:

Peter Buhl Jensen	Telephone	+45 39 17 83 92
CEO		Mobile	+45 21 60 89 22


Background information

About TopoTarget 
TopoTarget (OMX: TOPO) is an international biotech company headquartered in
Denmark, dedicated to finding ''Answers for Cancer'' and developing improved
cancer therapies. The company was founded and is run by clinical cancer
specialists and combines years of hands-on clinical experience with in-depth
understanding of the molecular mechanisms of cancer. 
TopoTarget has a broad clinical pipeline but is currently focusing on the
development of belinostat, which has shown proof of concept as monotherapy in
treating haematological malignancies and positive results in solid tumours
where it can be used in combination with full doses of chemotherapy, and is in
phase III in PTCL. TopoTarget's expertise in translational research is
utilizing its highly predictive in vivo and in vitro cancer models. TopoTarget
is directing its efforts on key cancer targets including HDACi, NAD+, mTOR,
FasLigand and topoisomerase II inhibitors. The company's first marketed product
Savene®/Totect® was approved by EMEA in 2006 and the FDA in 2007 and is
marketed by TopoTarget's own sales force in Europe and the US. For more
information, please refer to www.topotarget.com.